CrossrefInfokarte
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
ClinicoEconomics and Outcomes Research · 2025-04 · Volume 17 · 289-302
DOI: 10.2147/ceor.s501404 ↗Abstract
Kein Abstract verfügbar.
EUVIMED